Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights Multiple clinical trials across three AI-guided drug candidates are active with first expected data and readouts for LP-1

Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

Wire)-Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative

cancer therapies using its proprietary RADR AI and machine learning ("ML") platform with multiple clinical-stage

drug programs, today announced operational highlights and financial results for the fourth quarter and fiscal year ended December 31,

past quarter and the entire year of 2023 was a period of meaningful and remarkable progress for our programs and our AI platform at Lantern

Pharma. Our team demonstrated how combining emerging AI technologies, cancer biology models and experiments, chemical, molecular, and

multiomic biomarker data, along with large-scale patient data holds the promise of transforming timelines and costs in drug development

for oncology. We are very enthusiastic about 2024 and will be actively focused on meeting and possibly exceeding the milestones ahead

of us, which include potential initial data from our LP-184 Phase 1A trial; advancing the new company born from AI - Starlight

Therapeutics, which is focused wholly on CNS cancers; and progressing our ADC oncology program." said Panna Sharma, President and

CEO of Lantern Pharma."

continued, "Computational and AI-driven approaches are increasing their value-driving impact on oncology drug development, and

our team continues to increase the capabilities and usefulness of our platform while also helping to de-risk and sharpen the focus of

our existing clinical drug candidates. Our leadership in the innovative use of AI and machine learning to transform costs and timelines

in the development of precision oncology therapies has guided three drug development programs in active clinical trials. We believe this

pace of development with our focused team and resources should yield significant future benefits for investors and patients as our industry

matures, adopts and accepts a data and AI-centric approach to drug development."

of AI-Powered Pipeline:

has shown nanomolar potency across multiple published in vitro and in vivo studies, including mantle cell lymphoma (MCL), double hit

lymphoma (DHL), and other advanced NHL cancer subtypes with DNA damage response deficiencies, notably those with compromised functioning

of the ataxia-telangiectasia mutated (ATM) gene due to mutations or deletions.

all MCL, DHL, and High Grade B-Cell Lymphoma (HGBL) patients relapse from the current standard-of-care agents and there is an urgent

and unmet need for novel improved therapeutic options for these patients. In the US and Europe, MCL, DHL, and HGBLs are diagnosed in

16,000-20,000 patients each year and have an estimated annual market potential of over USD 3+ billion.

dosage and safety data obtained in the Phase 1A trial are expected to be used to advance the central nervous system (CNS) indications

for a future Phase 1b/2 trial to be sponsored by Lantern's wholly owned subsidiary, Starlight Therapeutics. Additionally, AI and

preclinical studies are ongoing to further refine drug combination studies supporting the use of LP-184 to improve the durability of

response and/or the overall response rates in combination with FDA approved drugs that are widely used in cancer treatment. Globally,

the aggregate annual market potential of LP-184's target indications is estimated to be approximately $12+ billion, consisting

of $4.5+ billion for CNS cancers and $7.5+ billion for solid tumors.

never-smokers with NSCLC are a growing population of patients and do not respond well to PD-1/PD-L1-based therapies, leaving them with

reduced treatment options. In the US, there are approximately 20,000-40,000 never-smokers with NSCLC diagnosed annually, representing

an estimated US annual market potential of $1.5 billion and a global estimated annual market potential of over $2.6 billion. Additional

information on the Harmonic trial can be found at the Harmonic website and clinicaltrials.gov.

Platform Growth and Development:

will potentially focus additional data growth efforts of the RADR platform on: drug sensitivity data, combination treatment

outcome data, and biomarker data in rare cancers, and on emerging synthetic lethal targets that are aimed at accelerating the development

of new therapies for Lantern and its partners. Additionally, the RADR platform's generative AI capabilities, focusing

on molecular optimization and automated feature extraction to improve understanding and prediction of molecular dynamics, safety, and

drug-drug interactions are planned to increase in functionality and scope in the coming quarters.

recently recruited a Starlight Chief Medical Officer who will focus on Starlight's clinical trials, development of personnel to

execute on the planned clinical strategy and overall support in corporate development activity. Starlight and Lantern plan on initiating

Phase 1B/2 clinical trials during the second half of 2024. The market potential for the currently planned indications for Starlight's

synthetically-lethal, cancer-cell DNA damaging agent - STAR-001 - is estimated to be $4.5 billion to $5+ billion USD across

both adult and pediatric primary and secondary CNS cancers.

leveraged RADR , a proprietary AI platform for oncology drug development, for target selection and molecular payload characterization

in ADCs, and a unique, controlled conjugation approach for maximizing drug-to-antibody ratios while controlling for non-specific conjugation.

Lantern expects to move towards IND development of the ADC program during 2024 with a focus on select solid tumors that are unresponsive

or refractory to current therapies.

Operational Highlights:

Quarter & Fiscal Year 2023 Financial Highlights:

Call and Webinar Details:

will host its 4th quarter & full year 2023 earnings call and webinar today, March 18, 2024, at 4:30 p.m. ET.

Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary

AI and machine learning (ML) platform, RADR , leverages over 60 billion oncology-focused data points and a library of

200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of

AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline

of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC)

program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials

in 2-3 years and at approximately $1.0 - 2.5 million per program.

lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. We have also established a wholly-owned

subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of our promising therapies for CNS and brain cancers,

many of which have no effective treatment options. Our AI-driven pipeline of innovative product candidates is estimated to have a combined

annual market potential of over $15 billion USD and have the potential to provide life-changing therapies to hundreds of thousands of

cancer patients across the world.

find more information at:

press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section

21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating

to: future events or our future financial performance; the potential advantages of our RADR platform in identifying drug

candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of

our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates

and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development

efforts of our internal drug discovery programs and the utilization of our RADR platform to streamline the drug development

process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk

and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate;

estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our

plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves

or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements

that use words such as "anticipate," "believe," "contemplate," "could," "estimate,"

"expect," "intend," "seek," "may," "might," "plan," "potential,"

"predict," "project," "target," "model," "objective," "aim,"

"upcoming," "should," "will," "would," or the negative of these words or other similar

expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results

to differ materially from those indicated by the forward-looking statements, such as (i) the risk that our research and the research

of our collaborators may not be successful, (ii) the risk that promising observations in preclinical studies do not ensure that later

studies and development will be successful, (iii) the risk that we may not be successful in licensing potential ADC candidates or in

completing potential partnerships and collaborations, (iv) the risk that none of our product candidates has received FDA marketing approval,

and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product

candidates, (v) the risk that no drug product based on our proprietary RADR AI platform has received FDA marketing approval

or otherwise been incorporated into a commercial product, and (vi) those other factors set forth in the Risk Factors section in our Annual

Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 18, 2024. You may

access our Annual Report on Form 10-K for the year ended December 31, 2023 under the investor SEC filings tab of our website at www.lanternpharma.com

or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking

statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements

will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this

presentation represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update

any forward-looking statements to conform the statement to actual results or changes in our expectations.

Pharma Disclosure Channels to Disseminate Information: